Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
ConditionIntestinal Disease
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, Irvine
About this trial
The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery
Eligibility criteria
Qualifiers
Age 18 or older
Laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission
Disqualifiers
Allergy to Rocuronium, Vecuronium, or Sugammadex
Bowel resection surgery requiring an ostomy
No severe valvulopathy, no systolic heart failure with reduced ejection fraction (HFrEF), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality
No autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no COPD with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin
Trial design
Treatments tested in this trial
- Neostigmine Injectable Solution
- Sugammadex injection
Treatment groups
128 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of California, Irvine
Lead sponsor
Merck Sharp & Dohme LLC
Collaborator
Source ClinicalTrials.gov